Drugs / Individualized ASO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07410143 | Jan → Sep 2026 overdue | — | EveryONE Medicines Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Individualized ASO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07410143 ↗ |
| Modality | Antisense oligonucleotide | “individualised antisense oligonucleotides (ASOs)” NCT07410143 ↗ |